Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-01-04 @ 4:29 PM
Study NCT ID:
NCT02644967
Status:
COMPLETED
Last Update Posted:
2022-08-03
First Post:
2015-12-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
Sponsor:
Idera Pharmaceuticals, Inc.